| Autor: |
Hegyi B; Department of Pharmacology University of California Davis CA., Mira Hernandez J; Department of Pharmacology University of California Davis CA.; Research Group in Veterinary Medicine (GIVET), School of Veterinary Medicine University Corporation Lasallista (Unilasallista) Caldas Antioquia Colombia., Ko CY; Department of Pharmacology University of California Davis CA., Hong J; Department of Pharmacology University of California Davis CA., Shen EY; Department of Pharmacology University of California Davis CA., Spencer ER; Department of Pharmacology University of California Davis CA., Smoliarchuk D; Department of Pharmacology University of California Davis CA., Navedo MF; Department of Pharmacology University of California Davis CA., Bers DM; Department of Pharmacology University of California Davis CA., Bossuyt J; Department of Pharmacology University of California Davis CA. |
| Abstrakt: |
Background The pathobiology of heart failure with preserved ejection fraction (HFpEF) is still poorly understood, and effective therapies remain limited. Diabetes and mineralocorticoid excess are common and important pathophysiological factors that may synergistically promote HFpEF. The authors aimed to develop a novel animal model of HFpEF that recapitulates key aspects of the complex human phenotype with multiorgan impairments. Methods and Results The authors created a novel HFpEF model combining leptin receptor-deficient db/db mice with a 4-week period of aldosterone infusion. The HFpEF phenotype was assessed using morphometry, echocardiography, Ca 2+ handling, and electrophysiology. The sodium-glucose cotransporter-2 inhibitor empagliflozin was then tested for reversing the arrhythmogenic cardiomyocyte phenotype. Continuous aldosterone infusion for 4 weeks in db/db mice induced marked diastolic dysfunction with preserved ejection fraction, cardiac hypertrophy, high levels of B-type natriuretic peptide, and significant extracardiac comorbidities (including severe obesity, diabetes with marked hyperglycemia, pulmonary edema, and vascular dysfunction). Aldosterone or db/db alone induced only a mild diastolic dysfunction without congestion. At the cellular level, cardiomyocyte hypertrophy, prolonged Ca 2+ transient decay, and arrhythmogenic action potential remodeling (prolongation, increased short-term variability, delayed afterdepolarizations), and enhanced late Na + current were observed in aldosterone-treated db/db mice. All of these arrhythmogenic changes were reversed by empagliflozin pretreatment of HFpEF cardiomyocytes. Conclusions The authors conclude that the db/db +aldosterone model may represent a distinct clinical subgroup of HFpEF that has marked hyperglycemia, obesity, and increased arrhythmia risk. This novel HFpEF model can be useful in future therapeutic testing and should provide unique opportunities to better understand disease pathobiology. |
Plný text